In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Histrelin | Natural peptide Oxytocin | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural peptide | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 246 | 3,492 (plus 1,148 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 48 (48 in people) | 157 (152 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 11 · 5 active3 more mention it but do not test it | 690 · 65 active238 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Histrelin | Oxytocin |
|---|---|---|
| Sex hormones and fertilityReproductive and sexual health | 1559560 | 1503286 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Pitocin says: “Antepartum: medically indicated induction of labor, stimulation or reinforcement of labor, adjunctive therapy in incomplete or inevitable abortion” No central EU authorisation (EMA).
| Adverse eventsWhole body | 4040 | 1261233 |
|---|
| Receptor activity and mechanismEndocrine and hormones | 422 | 28960801472 |
|---|
| PharmacokineticsPharmacology | 33 | 9168203 |
|---|
| Body weightMetabolic and weight | 11 | 23176 |
|---|
| Tumor growthCancer | 1212 | 6411 |
|---|
| Bone and jointMusculoskeletal | 66 | 2020 |
|---|
| Patient-reported outcomesWhole body | 11 | 22 |
|---|
| Quality of lifeWhole body | 11 | 22 |
|---|
| MortalityWhole body | 22 | 22 |
|---|
| Liver fat and liver functionLiver | 11 | 11 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Histrelin differs from Gonadorelin at 2 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Histrelin | Oxytocin |
|---|---|---|
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in effect size | No randomized trial result 3 results from other study designs. | −1.12 effect size Effect size Dose studied: 48 IU/day6 weeksn = 1032020 |
| Body weightMetabolic and weightCompared as: difference from placebo, in g | No randomized trial result 1 result from other study designs. | 196 g Difference in total fat Dose studied: 24 IU four times daily8 weeksn = 612024 |
| Liver fat and liver functionLiverCompared as: difference from placebo, in proportion | No randomized trial result 1 result from other study designs. | −0.01 proportion Difference in liver fat fraction Dose studied: 24 IU four times daily8 weeksn = 612024 |
| Sex hormones and fertilityEndocrine and hormonesCompared as: value in the arm that got the peptide, in % | No randomized trial result 155 results from other study designs. | 14.4% Mean percent change testosterone Dose studied: 24 IUn = 452020 |
| Receptor activity and mechanismNervous system and cognitionCompared as: value in the arm that got the peptide, in proteins | No randomized trial result 4 results from other study designs. | 198 proteins Differentially expressed proteins Dose studied: 24 IUsingle dosen = 192026 |
No randomized trial result
1 result from other study designs.
196 g
Difference in total fat
Dose studied: 24 IU four times daily8 weeksn = 612024
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 11 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Endo USA Inc., a Keenova Therapeutics Company36 participantsSept 2004 to Apr 2012
Central Precocious Puberty
NRG Oncology2,753 participants21 Jan 2021 to est. 31 Dec 2038
Prostate Adenocarcinoma · Stage III Prostate Cancer AJCC v8 · Stage IVA Prostate Cancer AJCC v8
NRG Oncology2,050 participants6 Dec 2021 to est. 11 Nov 2031
Prostate Adenocarcinoma
3 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 690 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
University of Alabama at Birmingham1,798 participantsNov 2008 to Jun 2010
Uterine Atony · Postpartum Hemorrhage
Northwestern University1,003 participants28 Sept 2015 to 28 Sept 2020
Dystocia
University of Zimbabwe506 participants8 Apr 2018 to 30 Jun 2019
Post Partum Hemorrhage
238 more mention it but do not test it. They only measure it or name it in their text.